• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Olaparib Monotherapy for -Mutated High-Grade Serous Endometrial Cancer.

作者信息

Nakamura Kohei, Aimono Eriko, Tanishima Shigeki, Imai Mitsuho, Nagatsuma Akiko Kawano, Hayashi Hideyuki, Yoshimura Yuki, Nakayama Kentaro, Kyo Satoru, Nishihara Hiroshi

机构信息

Genomics Unit, Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.

Department of Biomedical Informatics, Kansai Division, Mitsubishi Space Software, Tokyo, Japan.

出版信息

JCO Precis Oncol. 2020 Apr 9;4. doi: 10.1200/PO.19.00368. eCollection 2020.

DOI:10.1200/PO.19.00368
PMID:32923896
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7446499/
Abstract
摘要

相似文献

1
Olaparib Monotherapy for -Mutated High-Grade Serous Endometrial Cancer.奥拉帕利单药治疗BRCA突变的高级别浆液性子宫内膜癌。
JCO Precis Oncol. 2020 Apr 9;4. doi: 10.1200/PO.19.00368. eCollection 2020.
2
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.奥拉帕利单药维持治疗铂敏感复发性浆液性卵巢癌患者的总生存期：一项随机、安慰剂对照、双盲、2 期临床试验的更新分析。
Lancet Oncol. 2016 Nov;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X. Epub 2016 Sep 9.
3
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.奥拉帕利联合化疗治疗复发性铂类敏感卵巢癌：一项随机 2 期临床试验。
Lancet Oncol. 2015 Jan;16(1):87-97. doi: 10.1016/S1470-2045(14)71135-0. Epub 2014 Dec 4.
4
BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.BRCA 状态不能预测卡铂和奥拉帕利联合治疗高级别浆液性卵巢癌细胞系的协同作用。
Mol Pharm. 2018 Jul 2;15(7):2742-2753. doi: 10.1021/acs.molpharmaceut.8b00246. Epub 2018 Jun 1.
5
Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain.奥拉帕利对西班牙BRCA突变阳性、铂敏感复发高级别浆液性上皮性卵巢癌患者维持治疗的经济影响。
Farm Hosp. 2018 May 1;42(3):95-102. doi: 10.7399/fh.10904.
6
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.一项针对BRCA1或BRCA2突变的HER2阴性晚期乳腺癌一线治疗的I期试验，随后进行两个周期卡铂-奥拉帕利联合治疗，然后奥拉帕利单药治疗与卡培他滨对比的随机II期试验（REVIVAL）：一项随机对照试验的研究方案。
Trials. 2016 Jun 21;17(1):293. doi: 10.1186/s13063-016-1423-0.
7
Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer.奥拉帕利：用于卵巢癌维持治疗的研究进展。
BioDrugs. 2015 Apr;29(2):143-50. doi: 10.1007/s40259-015-0125-6.
8
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.接受化疗缓解后的铂类敏感型复发性高级别浆液性卵巢癌患者使用奥拉帕利胶囊维持治疗的长期疗效、耐受性和总生存期。
Br J Cancer. 2018 Oct;119(9):1075-1085. doi: 10.1038/s41416-018-0271-y. Epub 2018 Oct 24.
9
Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.奥拉帕利抑制 BRCA2 种系突变的卵巢癌患者来源异种移植瘤的生长。
Clin Cancer Res. 2011 Feb 15;17(4):783-91. doi: 10.1158/1078-0432.CCR-10-1382. Epub 2010 Nov 19.
10
Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report.奥拉帕利单药治疗BRCA2突变型难治性肝内胆管癌：一例报告
Onco Targets Ther. 2018 Sep 18;11:5957-5962. doi: 10.2147/OTT.S176914. eCollection 2018.

引用本文的文献

1
Potential role of Fanconi anemia pathway in the pathogenesis of endometrial cancer (Review).范可尼贫血通路在子宫内膜癌发病机制中的潜在作用（综述）
Mol Med Rep. 2025 Nov;32(5). doi: 10.3892/mmr.2025.13660. Epub 2025 Aug 24.
2
Expanding the Genomic Landscape of HBOC and Cancer Risk Among Mutation Carriers.拓展遗传性乳腺癌卵巢癌综合征（HBOC）的基因组格局及突变携带者的癌症风险
Int J Mol Sci. 2025 Jun 20;26(13):5928. doi: 10.3390/ijms26135928.
3
Mutations in homologous recombination repair genes in patients with metastatic endometrial cancer: association with clinical characteristics and prognosis.

本文引用的文献

1
Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types.多种癌症类型中同源重组相关基因突变的患病率。
JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00286. Epub 2018 Jul 23.
2
Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.100例无BRCA1和BRCA2突变的日本家族性乳腺癌病例中RAD51C、PALB2和BRIP1的突变状态
Cancer Sci. 2017 Nov;108(11):2287-2294. doi: 10.1111/cas.13350. Epub 2017 Sep 18.
3
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
转移性子宫内膜癌患者同源重组修复基因的突变：与临床特征及预后的关联
J Gynecol Oncol. 2025 Jul;36(4):e62. doi: 10.3802/jgo.2025.36.e62. Epub 2025 Jan 26.
4
Clinical application of whole-genome sequencing of solid tumors for precision oncology.实体瘤全基因组测序在精准肿瘤学中的临床应用。
Exp Mol Med. 2024 Aug;56(8):1856-1868. doi: 10.1038/s12276-024-01288-x. Epub 2024 Aug 13.
5
Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.原发性乳腺癌各亚型的同源重组缺陷。
JCO Precis Oncol. 2023 Sep;7:e2300338. doi: 10.1200/PO.23.00338.
6
Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial Adenocarcinoma.一名IVB期复发性子宫内膜样腺癌患者对PARP抑制剂奥拉帕尼的完全病理反应
J Clin Med. 2023 Jun 4;12(11):3839. doi: 10.3390/jcm12113839.
7
Targeting homologous recombination deficiency in uterine leiomyosarcoma.针对子宫平滑肌肉瘤的同源重组缺陷。
J Exp Clin Cancer Res. 2023 May 4;42(1):112. doi: 10.1186/s13046-023-02687-0.
8
Spectrum of BRCA1 interacting helicase 1 aberrations and potential prognostic and therapeutic implication: a pan cancer analysis.BRCA1 相互作用解旋酶 1 异常的谱及其潜在的预后和治疗意义：泛癌分析。
Sci Rep. 2023 Mar 17;13(1):4435. doi: 10.1038/s41598-023-31109-6.
9
Estimating copy number to determine BRCA2 deletion status and to expect prognosis in localized prostate cancer.评估拷贝数以确定 BRCA2 缺失状态并预测局限性前列腺癌的预后。
Cancer Med. 2023 Apr;12(7):8154-8165. doi: 10.1002/cam4.5617. Epub 2023 Jan 16.
10
Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology.胚系 DNA 修复缺陷与精准肿瘤学的治疗相关性
Cancer Treat Rev. 2022 Mar;104:102337. doi: 10.1016/j.ctrv.2021.102337. Epub 2022 Jan 5.
同源重组缺陷：利用卵巢癌的根本脆弱性
Cancer Discov. 2015 Nov;5(11):1137-54. doi: 10.1158/2159-8290.CD-15-0714. Epub 2015 Oct 13.
4
Endometrial cancer.子宫内膜癌。
Lancet. 2016 Mar 12;387(10023):1094-1108. doi: 10.1016/S0140-6736(15)00130-0. Epub 2015 Sep 6.
5
Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases.聚（ADP - 核糖）聚合酶（PARP）作用机制综述以及在癌症和其他疾病中作为靶向治疗的理论依据。
Crit Rev Eukaryot Gene Expr. 2014;24(1):15-28. doi: 10.1615/critreveukaryotgeneexpr.2013006875.
6
Integrated genomic characterization of endometrial carcinoma.子宫内膜癌的综合基因组特征分析。
Nature. 2013 May 2;497(7447):67-73. doi: 10.1038/nature12113.
7
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.基因组杂合性丢失模式预测上皮性卵巢癌同源重组修复缺陷。
Br J Cancer. 2012 Nov 6;107(10):1776-82. doi: 10.1038/bjc.2012.451. Epub 2012 Oct 9.
8
Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.倍性和大规模基因组不稳定性一致鉴定出具有 BRCA1/2 失活的基底样乳腺癌。
Cancer Res. 2012 Nov 1;72(21):5454-62. doi: 10.1158/0008-5472.CAN-12-1470. Epub 2012 Aug 29.
9
Molecular targets and targeted therapeutics in endometrial cancer.子宫内膜癌的分子靶点和靶向治疗。
Curr Opin Oncol. 2012 Sep;24(5):554-63. doi: 10.1097/CCO.0b013e328354e585.
10
Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.端粒等位基因不平衡表明DNA修复缺陷以及对DNA损伤剂敏感。
Cancer Discov. 2012 Apr;2(4):366-375. doi: 10.1158/2159-8290.CD-11-0206. Epub 2012 Mar 22.